IQ-AI Limited Submission of FDA 510(k) Application for IB Zero G (3069N)
31 May 2022 - 5:00PM
UK Regulatory
TIDMIQAI
RNS Number : 3069N
IQ-AI Limited
31 May 2022
31 May 2022
IQ-AI Limited
("IQ-AI" or the "Company")
Imaging Biometrics Submits FDA 510(k) Application for IB Zero
G
Patented Artificial Intelligence Technology Eliminates the Need
for Gadolinium-Based Contrast Agents in MRI Exams
Milwaukee - 31 May 2022: Imaging Biometrics, LLC (IB), a
subsidiary of IQ-AI Limited, (OTCQB: IQAIF) (LSE: IQAI), today
announced it has submitted an FDA 510(k) application for IB Zero
G(TM); the patented artificial intelligence (AI) software that
eliminates the need for gadolinium-based contrast agents ("GBCAs")
in routine magnetic resonance imaging ("MRI") exams. The zero-dose
GBCA exam offers potential benefits which include reduced concerns
associated from the long-term side effects of repeated GBCA use, a
more comfortable patient experience, and more productive radiology
departments.
The FDA 510(k) submission is the first step in potentially
transforming the global GBCA market and introducing a paradigm
shift in radiology departments. Eliminating the need to
intravenously inject GBCAs, without compromising the diagnostic
quality of MRI exams, has the potential to benefit millions of
patients annually. Patients with reduced kidney function who cannot
tolerate GBCAs, children, and others where there are concerns about
the potential effects of gadolinium retention in the body are
particularly relevant to the availability of a zero-dose
alternative.
"In addition to the potential benefits of eliminating or
reducing the routine use of GBCAs, the recent world-wide shortages
of iodinate contrast agents have illustrated how vulnerable routine
radiology operations have become to the continuation of
smooth-running global supply chains which we have previously taken
for granted," said Trevor Brown, CEO of IQ-AI Limited.
The Directors of the Company accept responsibility for the
contents of this announcement.
-ENDS-
For further information, please contact:
IQ-AI Limited
Trevor Brown/Brett Skelly/Vinod Kaushal
Tel: 020 7469 0930
Peterhouse Capital Limited (Financial Adviser and Broker)
Lucy Williams/Heena Karani
Tel: 020 7220 9797
About IQ-AI Limited
IQ-AI Limited, (LON: IQAI) (OTCQB: IQAIF), the parent company of
Wisconsin-based Imaging Biometrics, LLC (IB), is focused on
delivering quantitative imaging platforms and therapeutics that
transform how clinicians diagnose and treat patients more
efficiently and effectively. For more information about Imaging
Biometrics, visit the company's website at
www.imagingbiometrics.com
Safe Harbor Statement
This press release includes statements that may constitute
forward-looking statements made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
These forward-looking statements can be identified by terminology
such as "will," "expects," "anticipates," "future," "intends,"
"plans," "believes," "estimates," or the negative of these words
and/or similar statements. Statements that are not historical
facts, including statements about the Company's beliefs and
expectations, are forward-looking statements. Forward-looking
statements involve inherent risks and uncertainties that could
cause actual results to differ materially from the forward-looking
statements. For example, statements about future revenues and the
Company's ability to fund its operations and contractual
obligations are forward looking and subject to risks. Several
important factors could cause actual results to differ materially
from those contained in any forward-looking statement. Potential
risks and uncertainties include, but are not limited to, the
inability to raise capital to support the Company through its
growth stage, the Company's inability to generate projected sales
and trade relations between the United States and China. The
Company does not undertake any obligation to update any
forward-looking statement, except as required under applicable
law.
Market Abuse Regulation (MAR) Disclosure
This announcement contains inside information for the purposes
of Article 7 of the Market Abuse Regulation EU 596/2014 as it forms
part of retained EU law (as defined in the European Union
(Withdrawal) Act 2018).
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
UPDSDDFMSEESEII
(END) Dow Jones Newswires
May 31, 2022 03:00 ET (07:00 GMT)
Iq-ai (LSE:IQAI)
Historical Stock Chart
From Apr 2024 to May 2024
Iq-ai (LSE:IQAI)
Historical Stock Chart
From May 2023 to May 2024